Dulaglutide is the active ingredient in Trulicity, an Eli Lilly injectable approved for type 2 diabetes. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, the same broad class as semaglutide and liraglutide. The U.S. Food and Drug Administration approved it on September 18, 2014; the European Medicines Agency followed in November 2014.
Unlike many research peptides, dulaglutide is a fully approved prescription drug with a long published evidence base. None of what follows is medical or dosing advice.
What it is
Dulaglutide is a recombinant fusion protein. It joins a modified GLP-1(7-37) peptide to a fragment (the Fc region) of a human IgG4 antibody. That design matters for how the drug behaves. Native GLP-1 is broken down within minutes by the enzyme DPP-4 and cleared by the kidneys. Bolting the peptide onto a large antibody fragment shields it from DPP-4 and slows clearance, which pushes the human half-life out to roughly 90 hours. That is what makes once-weekly dosing possible (DrugBank / Glaesner et al., 2010).
How it works
GLP-1 is an incretin hormone the gut releases after eating. Dulaglutide mimics it by binding the GLP-1 receptor on pancreatic beta cells, raising intracellular cyclic AMP and triggering insulin release. The effect is glucose-dependent, meaning insulin is secreted when blood sugar is elevated. The drug also suppresses glucagon, slows gastric emptying, and reduces appetite. Because its mechanism depends on functioning beta cells producing insulin, it is not indicated for type 1 diabetes (FDA prescribing information).
What the research shows
The AWARD program was the set of phase 3 trials that supported approval. Across five of the six core AWARD studies, once-weekly dulaglutide 1.5 mg lowered HbA1c more than its active comparators, which included exenatide, insulin glargine, metformin, and sitagliptin (Jendle et al., 2016, review). Later trials added higher 3.0 mg and 4.5 mg doses.
The most cited cardiovascular study is REWIND, published in The Lancet in 2019. It randomized 9,901 people with type 2 diabetes to dulaglutide 1.5 mg weekly or placebo and followed them for a median of 5.4 years. Most participants (about 69%) had no prior cardiovascular disease at enrollment. Dulaglutide cut the rate of major adverse cardiovascular events, a composite of non-fatal heart attack, non-fatal stroke, or cardiovascular death, by 12% (Gerstein et al., REWIND, Lancet 201931149-3/abstract)). That result is why the FDA label now includes reducing major cardiovascular events in adults with type 2 diabetes who have established heart disease or multiple risk factors.
In 2022 the FDA extended approval to children aged 10 and older with type 2 diabetes, based on a 26-week placebo-controlled trial in 154 pediatric patients.
Regulatory and quality notes
Approved uses are narrow: glycemic control in type 2 diabetes (adults and children 10+) and cardiovascular event risk reduction in the at-risk group above. Available pen strengths are 0.75, 1.5, 3.0, and 4.5 mg. Dulaglutide is not approved for weight loss or obesity, even though weight reduction shows up as an effect in trials. Semaglutide and tirzepatide, not dulaglutide, carry the obesity indications.
As a peptide drug, dulaglutide is also relevant to anti-doping. GLP-1 agonists are not currently named on the WADA Prohibited List, but athletes should confirm status directly with WADA and their sport's authority before assuming anything.
A buyer-side caution: the only properly characterized dulaglutide is the licensed Trulicity pen, manufactured under regulated conditions with documented identity and purity. Material sold through gray-market or "research only" channels has no such guarantee. A 60 kDa fusion protein is difficult to synthesize and verify, and a certificate of analysis from an unaccredited seller does not establish that what is in the vial is intact, correctly folded dulaglutide. Independent third-party identity and purity testing is the only way to check those claims, and it is the kind of evidence this site aggregates when available. Nothing here is medical or dosing advice.